Background. Adjuvant endocrine therapy (AET) has been shown to reduce the risk of second breast cancer events in women with ductal carcinoma in situ (DCIS). There is no population-level evaluation of AET use in DCIS patients after standardized reporting of estrogen receptor (ER) status in cancer registries in 2004. Methods. We conducted a retrospective cohort study of women with DCIS in the National Cancer Data Base between 2005 and 2012. Patient, tumor, and treatment characteristics as well as temporal trends associated with receipt of AET were evaluated by generalized linear regression. Results. Among 206,255 DCIS patients, 36.5 % received AET. Fewer than half of ER-positive patients (n = 62,146, 46.4 %) received AET, with a modest but significant increase over time (43.6 % in 2005 to 47.5 % in 2012; unadjusted p trend \0.001). AET decreased among ERnegative patients (8.9-6.5 %, p trend \0.001) over the same time period. On multivariate analysis, younger (\40 years) and older (C70 years) women were less likely to receive AET than 50-to 59-year-old women (\40 years: relative risk 0.86, 95 % confidence interval 0.82-0.89; C70 years: relative risk 0.79, 95 % confidence interval 0.77-0.81). ER-positive status conferred a 6.15-fold higher likelihood of receiving AET compared to ER-negative status (95 % confidence interval 5.81-6.50). Women who underwent breast-conserving surgery (BCS) with adjuvant radiotherapy were most likely to receive AET. Conclusions. Receipt of AET is relatively low in the group of women most likely to benefit from its use, namely ER-positive patients who underwent BCS. Significant variation exists with respect to patient, tumor, site, and treatment factors. More tolerable drugs or clearer guideline recommendations may increase use.
Ductal carcinoma in situ (DCIS) is a stage 0 breast cancer that accounts for 20 % of screen-detected breast malignancies. 1 Goals of treatment include prevention of second breast cancer events or evolution into invasive cancer. Standard-of-care treatment of DCIS includes either breast-conserving surgery (BCS) with adjuvant radiotherapy or mastectomy. Approximately 6-30 % of women will experience a second breast cancer event after surgical excision of DCIS, at least half of which will be invasive and confer a risk of breast cancer mortality. [2] [3] [4] [5] [6] Randomized trials have demonstrated the efficacy of tamoxifen as adjuvant endocrine therapy (AET) in preventing second breast events in women with DCIS compared to placebo. 7, 8 On the basis of these findings, National Comprehensive Cancer Network guidelines recommend consideration of 5 years of tamoxifen treatment for patients with DCIS, particularly if estrogen receptor (ER) positive. 9 Exemestane has also been shown to lower the risk of a contralateral breast cancer event after unilateral mastectomy for DCIS, providing another possible adjuvant option for postmenopausal women. 10 The heterogeneous potential for invasion and recurrence in DCIS has led to controversy regarding appropriate initial management, and studies have shown marked differences in patterns of care and physician opinions regarding optimal treatment. 11 Despite the known benefits of AET, studies have revealed variable levels of acceptance and compliance ranging between 41 and 66 %. [12] [13] [14] [15] [16] Several of these studies were unable to account for ER status, an important factor in AET treatment.
The objective of our study was to conduct a populationlevel evaluation of trends and characteristics associated with AET use among women with DCIS in a time period that included standardized reporting of ER status in national cancer registries.
METHODS

Data Source and Study Cohort
We utilized the National Cancer Data Base (NCDB), a joint project of the Commission on Cancer, the American College of Surgeons, and the American Cancer Society that contains sociodemographic, tumor, treatment, and outcome characteristics for approximately 70 % of all new cancer diagnoses in the United States annually. 17 We retrospectively identified all female patients aged 21 years or older with a diagnosis of unilateral DCIS between 2005 and 2012 (n = 284,621). Histologic diagnoses were based on the International Classification of Disease for Oncology, 3rd edition (ICD-O-3), codes for DCIS (8201/2, 8230/2, 8500/2, 8503/2, 8507/2, 8523/2, 8501/2). Patients with any previous cancer (n = 70,637) were excluded from the analysis, as were patients who did not undergo surgical excision because they could not be distinguished from those diagnosed by autopsy or death (n = 7729). The institutional review board of the Fred Hutchinson Cancer Research Center approved this retrospective study.
Study Variables
The primary outcome-receipt of AET within the first year after DCIS diagnosis-was categorized as a multilevel categorical variable for descriptive purposes and as a binary variable indicating receipt or nonreceipt of AET for trend and multivariate analyses. The categorical variable was characterized as follows: AET not planned as part of therapy; received AET; AET not administered as a result of contraindication; AET recommended but not administered (no reason provided); AET recommended but not administered (patient refused); and AET recommended, unknown whether given. AET nonreceipt for the binary variable included patients who did not have AET planned as part of therapy and those who were recommended AET but did not receive it for any of the above reasons. Other study covariates included patient demographics, tumor characteristics, site characteristics, and treatment factors (Table 1) .
Facility locations were categorized into regions according to the 2000 United States census: Northeast, Southeast, Atlantic, Great Lakes, South, Midwest, West, Mountain, and Pacific. Facility types were defined as community cancer program (100-500 newly diagnosed cases per year), comprehensive community cancer program (C500 newly diagnosed cases per year) and academic/research program (C500 newly diagnosed cases per year and participation in physician education and research). A multilevel categorical treatment variable included BCS without radiotherapy, BCS with radiotherapy, unilateral mastectomy, and bilateral mastectomy.
Statistical Analysis
STATA/SE 12.1 software (StataCorp, College Station, TX) was used for all analyses. Descriptive statistics were examined overall and by AET status. Patient demographic, tumor, site, and treatment characteristics were compared univariately between patients who received or who did not receive AET by Chi square tests. All factors were significantly associated with receipt of AET and were included in multivariate estimates. Patients with a contraindication for AET (n = 4063) were excluded from multivariate analysis. Because the data set was only 63 % complete for all variables, missing values for all study covariates listed in Table 1 were estimated using multiple imputation with chained equations over ten iterations. 18 Regression analyses used the combined results of the ten imputations to create valid statistical inferences that account for biases in estimates associated with missing data. 19 Because receipt of AET was not expected to be a rare event, we estimated relative risks using generalized linear models with a loglink function, specifying a Poisson distribution and clustering on NCDB facility site. 20 Two-sided p values of \0.05 were considered statistically significant.
RESULTS
Demographic, Tumor, and Treatment Characteristics
We identified 206,255 patients diagnosed with unilateral DCIS between 2005 and 2012. The median age was 58 years, and the majority of patients were white (81.8 %), had no comorbid conditions (87.9 %), were privately insured (63.3 %), and received treatment at a comprehensive community cancer program (60.0 %) ( Table 1) . Ninety-six percent had negative margins. Half of patients (Fig. 1 ). Contraindications were rare (n = 4063, 2.1 %), as was patient refusal of AET after recommendation by a treating physician (n = 14,001, 7.1 %). Among ER-positive patients, fewer than half (n = 62,146, 46.4 %) received AET. There was a modest but significant increase over time from 43.6 % in 2005 to 47.5 % in 2012 (unadjusted p trend \0.001). Conversely, the proportion of ER-negative patients who received AET decreased during the same time interval, from 8.9 to 6.5 % (unadjusted p trend \0.001). Temporal trends observed for AET use among ER-positive and ER-negative patients remained significant in multivariate analysis after adjusting for all covariates that changed over the time period of the study.
The proportion of patients who received AET according to patient demographic, tumor, site, and treatment characteristics are summarized in Table 1 . In univariate analyses, patients in the youngest (\40 years) and oldest (C70 years) age groups were the least likely to receive AET. Characteristics associated with a higher likelihood of receiving AET were well or moderately differentiated DCIS, ER-positive status, black race, treatment at a community cancer program, or treatment in the Northeast, Atlantic, Great Lakes, or Midwest. Negative pathologic margins and BCS followed by adjuvant radiotherapy were also associated with receipt of AET.
In multivariate analyses, numerous factors remained independently associated with receipt of AET ( Table 2) . Women aged 50-59 years were the most likely to receive AET, whereas women \40 and C70 years were least likely. Women with ER-positive DCIS were 6.15 times more likely to receive AET than women with ER-negative DCIS (95 % confidence interval 5.81-6.50). Compared to patients with positive margins or well-differentiated (Fig. 2) . Likewise, variation existed by type of surgical treatment (Fig. 3) . Women who underwent BCS alone, unilateral mastectomy, or bilateral mastectomy were significantly less likely to receive AET compared to women who underwent BCS followed by adjuvant radiotherapy.
DISCUSSION
Randomized controlled trials have demonstrated 31-66 % reduced relative risk of second breast cancer events among women who received AET for DCIS. 7, 8, 10, 21, 22 Despite this proven benefit, studies have shown highly variable AET use among DCIS patients, ranging from a low of 15 % to a high of 73 %. [12] [13] [14] [15] [16] [23] [24] [25] To our knowledge, this is the first population-based study of AET for DCIS in the contemporary era of standardized ER reporting. The results of our study indicate that among women who can expect the greatest potential AET benefit, those with ER-positive DCIS, only 46 % received AET. Reassuringly, we found that only 3 % of patients who received AET were ER negative. This finding, coupled with the fact that there was a significant decrease in the proportion of patients for whom ER testing was not performed or not available (29 % in 2005 to 7 % in 2012), suggests that immunohistochemical ER staining has become widely adopted for DCIS and that test results are appropriately guiding clinical management.
Type of initial treatment was significantly associated with receipt of AET. Not surprisingly, women who underwent bilateral mastectomy were least likely to receive AET, as there is no evidence that AET benefits this population. However, given the National Surgical Breast and Bowel Project (NSABP) B-06 and B-17 trial results that demonstrated higher local recurrence rates for BCS alone compared to either mastectomy or BCS with adjuvant radiotherapy, respectively, we found it surprising that patients undergoing BCS alone were less likely to receive AET. 4, 26 Likewise, despite a two to three times increased risk of local recurrence with positive pathologic margins, these women were significantly less likely to receive AET than those with negative margins. 4, 27 Possible explanations for these findings may be that patients who chose to undergo mastectomy for DCIS harbored more extensive disease, had strong family histories of disease, or had increased anxiety regarding recurrence. These patients may have been more inclined to accept elective AET as chemoprevention. Conversely, it may be that the physicians of or patients who elect to undergo BCS without radiotherapy, or those who do not have further surgery for positive margins, consciously chose to treat DCIS less aggressively by forgoing AET.
Patient age was also significantly associated with AET receipt. Women who were younger (\40 years) and older (C70 years) were the least likely to receive AET. Decreased utilization in the younger age group may be explained by the fact that tamoxifen administration is not compatible with childbearing, and aromatase inhibitors are not recommended in premenopausal women with intact ovarian function. 28 All AETs can cause undesirable adverse effects, including hot flashes and vaginal dryness, and tamoxifen carries a 2-to 4-fold increased risk of endometrial cancer and twofold increased risk of venous thromboemobolism. 29, 30 Previous studies have also shown a decline in receipt of AET with increasing age, which may be due to concerns of heightened risk of venous thromboembolism and endometrial cancer in older women. 24, 25, 31 It may also reflect an acceptance of findings from studies that demonstrated acceptably low breast cancer recurrence and mortality rates with the omission of select aspects of adjuvant breast cancer treatment in elderly women with early stage invasive breast cancer. 32, 33 There is considerable controversy regarding optimal treatment of DCIS, given its heterogeneity and survivability. [23] [24] [25] 34 Some clinicians have even advocated eliminating the use of the term ''carcinoma'' from the description of DCIS. 35 It is not surprising, therefore, that we found wide variation in receipt of AET across geographic location and treatment facility type. A survey of DCIS management among radiation oncologists demonstrated substantial differences in the likelihood of recommendation of adjuvant tamoxifen in DCIS patients. Fifty-six percent of survey respondents stated they would always recommend, 20 % if additional breast cancer risk factors, 11 % if family history, and 6 % very rarely or never. 11 Studies evaluating AET initiation point to the critical role of physicians. In a study of invasive cancer patients, 63 % of patients who did not initiate AET cited ''clinician factors'' as the primary reason. These included lack of adequate information about adverse effects and allowing for independent patient decision making. 36 Our finding that only 7 % of women refused AET when it was recommended substantiates this claim. Similar results are seen in studies including only DCIS patients. Physician recommendation for ''necessary'' rather than ''optional'' AET treatment in DCIS has been associated with 11-fold increased odds of use, suggesting that one of the primary factors associated with AET acceptance is how AET is presented to patients-as chemoprevention or as necessary treatment.
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One of the main strengths of this study is that the NCDB is estimated to capture approximately 70 % of all new DCIS diagnoses and thus is an informative reflection of nationwide practice patterns. However, there are limitations, including our inability to assess patient-or physicianlevel decision making regarding recommendations for and acceptance of AET. We were unable to assess AET compliance, which limits our ability to extrapolate to long-term AET use. Additionally, the NCDB does not provide information on the specific type of AET being offered to patients, family history, or BRCA status, all of which may have affected a patient's likelihood of acceptance. Misclassification or under-ascertainment of AET use based on chart abstraction is possible, but data abstractors have a rigorous process by which they classify and follow up with patients, so these biases should be minimal.
This study demonstrates that receipt of AET among patients with DCIS remains low in the modern era, and variability exists according to patient, tumor, and treatment characteristics. Absolute decreases in risk remain modest, and the low breast cancer-related mortality associated with DCIS (\5 % at 15 years) is not changed with the addition of adjuvant AET. 4 In the context of serious concerns about potential adverse effects and health risks, it remains challenging to convince clinicians and patients that the benefits of AET outweigh the risks. Regardless of these drawbacks, AET has been shown to decrease second invasive breast cancer events, which should not be dismissed. There are also substantial risks associated with breast cancer treatment, not to mention increased patient anxiety and decreased quality of life. Individualized risk-benefit discussions should be pursued with all patients. Aromatase inhibitors, now commonly used as AET in among postmenopausal women with invasive breast cancer, is a potential option for patients with DCIS, though not currently approved by the U.S. Food and Drug Administration for this indication. The recent IBIS-II and NCIC Clinical Trials Group MAP.3 prospective randomized trials demonstrated between 50 and 65 % relative reduction in invasive breast cancer among high-risk postmenopausal women receiving anastrazole or exemestane, respectively, compared to placebo. 10, 22 Contraindications associated with use are fewer for aromatase inhibitors compared to tamoxifen, and DCIS patients have shown improved longterm compliance with aromatase inhibitors. 16, 28 The ability to offer patients a wider variety of adjuvant treatment options with different, and possibly more tolerable, adverse effect profiles, is one aspect that could potentially improve acceptance of AET. Our findings also serve to highlight the need for better consensus and clearer national guidelines DISCLOSURE The authors declare no conflict of interest.
